{"id":"NCT01400425","sponsor":"Avid Radiopharmaceuticals","briefTitle":"Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline","officialTitle":"Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2011-07-22","resultsPosted":"2013-03-22","lastUpdate":"2013-03-29"},"enrollment":239,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Progressive Cognitive Decline"],"interventions":[{"type":"DRUG","name":"florbetapir F 18","otherNames":["18F-AV-45","Amyvid","florbetapir"]}],"arms":[{"label":"Subjects with Progressive Cognitive Decline","type":"EXPERIMENTAL"}],"summary":"The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.","primaryOutcome":{"measure":"Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Negative Florbetapir F 18 PET Scan.","timeFrame":"6 weeks","effectByArm":[{"arm":"Subjects With Progressive Cognitive Decline","deltaMin":56.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":229},"commonTop":["Headache","Diarrhoea","Nausea","Urinary tract infection","Back pain"]}}